Key Points
- CEO Robert Barrow sold 19,023 shares of Definium Therapeutics at an average price of $37.94, generating $721,732.62. He retained 1,494,640 shares worth approximately $56.7 million, a 1.26% reduction in his position.
- Definium’s stock opened at $38.09, with a $5.12 billion market capitalization, after the company reported a quarterly loss of $1.44 per share—well below analysts’ expected loss of $0.55.
- Analysts remain broadly positive, with the stock carrying a consensus “Buy” rating and an average price target of $63.00, despite the recent insider selling and earnings miss.
-inc-logo-1200x675.jpg?v=20240515130629)
Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) CEO Robert Barrow sold 19,023 shares of Definium Therapeutics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62. Following the completion of the transaction, the chief executive officer directly owned 1,494,640 shares of the company's stock, valued at approximately $56,706,641.60. This represents a 1.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Robert Barrow also recently made the following trade(s):
- On Thursday, June 25th, Robert Barrow sold 29,208 shares of Definium Therapeutics stock. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24.
Definium Therapeutics Stock Up 0.2%
NASDAQ:DFTX opened at $38.09 on Friday. The firm has a market capitalization of $5.12 billion, a PE ratio of -11.10 and a beta of 2.23. The stock has a 50 day moving average of $43.70 and a 200-day moving average of $29.49. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics, Inc. has a 52 week low of $8.77 and a 52 week high of $49.70.
Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts predict that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.
Hedge Funds Weigh In On Definium Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. Nykredit A S bought a new stake in Definium Therapeutics during the second quarter worth about $45,000. BNP Paribas Financial Markets grew its stake in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock worth $55,000 after buying an additional 3,020 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Definium Therapeutics during the third quarter worth approximately $126,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Definium Therapeutics during the fourth quarter worth approximately $254,000. 27.91% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several brokerages have commented on DFTX. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the stock an "outperform" rating in a research report on Monday, June 22nd. Needham & Company LLC boosted their target price on shares of Definium Therapeutics from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Citigroup reaffirmed a "buy" rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Bank of America assumed coverage on Definium Therapeutics in a report on Tuesday, August 18th. They issued a "buy" rating and a $75.00 target price on the stock. Finally, Wells Fargo & Company raised their price target on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $63.00.
View Our Latest Analysis on DFTX
Definium Therapeutics Company Profile
(
Get Free Report)
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
